1.84
price up icon1.10%   0.02
pre-market  プレマーケット:  1.91   0.07   +3.80%
loading
前日終値:
$1.82
開ける:
$1.82
24時間の取引高:
3.20M
Relative Volume:
1.23
時価総額:
$385.80M
収益:
$95,000
当期純損益:
$-327.27M
株価収益率:
-0.8679
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
-4.17%
1か月 パフォーマンス:
-1.60%
6か月 パフォーマンス:
-34.98%
1年 パフォーマンス:
-40.45%
1日の値動き範囲:
Value
$1.78
$1.905
1週間の範囲:
Value
$1.78
$2.10
52週間の値動き範囲:
Value
$1.78
$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
361
Name
Twitter
@AllogeneTx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

ALLO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.84 385.80M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
Jan 20, 2025

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN

Jan 20, 2025
pulisher
Jan 20, 2025

Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Jan 20, 2025
pulisher
Jan 19, 2025

Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL

Jan 19, 2025
pulisher
Jan 15, 2025

Barclays PLC Buys 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

JPMorgan Chase & Co. Sells 37,348 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Zacks Research Issues Pessimistic Estimate for ALLO Earnings - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

What is Zacks Research's Forecast for ALLO Q2 Earnings? - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $9.73 Consensus Price Target from Brokerages - MarketBeat

Jan 12, 2025
pulisher
Jan 10, 2025

Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World

Jan 10, 2025
pulisher
Jan 02, 2025

Geode Capital Management LLC Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLC - Defense World

Jan 02, 2025
pulisher
Dec 26, 2024

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance

Dec 26, 2024
pulisher
Dec 26, 2024

Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart

Dec 26, 2024
pulisher
Dec 26, 2024

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga

Dec 26, 2024
pulisher
Dec 24, 2024

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance

Dec 24, 2024
pulisher
Dec 24, 2024

State Street Corp Has $19.64 Million Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 24, 2024
pulisher
Dec 18, 2024

Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com

Dec 18, 2024
pulisher
Dec 18, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 18, 2024
pulisher
Dec 16, 2024

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2024
pulisher
Dec 16, 2024

Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Dec 16, 2024
pulisher
Dec 15, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat

Dec 15, 2024
pulisher
Dec 15, 2024

Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - MSN

Dec 15, 2024
pulisher
Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada

Dec 13, 2024
pulisher
Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 12, 2024

Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector Decline - GuruFocus.com

Dec 12, 2024
pulisher
Dec 12, 2024

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times

Dec 12, 2024
pulisher
Dec 12, 2024

Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire

Dec 12, 2024
pulisher
Dec 11, 2024

Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com

Dec 11, 2024
pulisher
Dec 11, 2024

Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com

Dec 11, 2024
pulisher
Dec 10, 2024

Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha

Dec 10, 2024
pulisher
Dec 10, 2024

Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com

Dec 09, 2024
pulisher
Dec 06, 2024

Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 06, 2024
pulisher
Dec 03, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decrease in Short Interest - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

Allogene Therapeutics Loses 23% Year To Date: How To Play The Stock? - Barchart

Dec 02, 2024
pulisher
Nov 29, 2024

Vestal Point Capital LP Trims Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Nov 29, 2024
pulisher
Nov 28, 2024

Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells - BioWorld Online

Nov 28, 2024
pulisher
Nov 23, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2024
pulisher
Nov 22, 2024

ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth? - Simply Wall St

Nov 22, 2024
pulisher
Nov 20, 2024

Allogene stock touches 52-week low at $2 amid market challenges - Investing.com India

Nov 20, 2024

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):